Genome Analyzer optimizes expression profiling resolution.

Press Release Summary:



Human GW (genome wide) SpliceArray(TM) enables research and clinical communities to proceed with comprehensive analysis of human genome. It monitors 23,000+ human genes, covering 130,000+ expressed transcripts, and requires over 6 million probes to help elucidate diversity of human proteome. Able to detect all known and novel expressed transcripts, solution interrogates both exons and splice junctions to accelerate diagnosis of chronic diseases.



Original Press Release:



ExonHit Launches Human Genome-Wide Splicearray(TM) to Enhance the Resolution of Expression Profiling



PARIS, France, February 20 -- ExonHit Therapeutics S.A. (Alternext: ALEHT), a drug and diagnostic discovery company, announces today the availability of its new SpliceArray(TM) which will enable the research and clinical communities to proceed with the most comprehensive analysis of the human genome. This SpliceArray(TM), available through our portfolio of genomic services, provides a unique approach to detect all known and novel expressed transcripts.

The Human GW SpliceArrayTM monitors over 23,000 human genes covering over 130,000 expressed transcripts and requires over 6 million probes to help elucidate the enormous diversity of the human proteome. This new design, manufactured on the Affymetrix platform, now expands our product offering and provides researchers the opportunity to obtain gene expression results at a resolution previously unattainable on a single microarray by interrogating both exons and splice junctions.

"ExonHit continues to expand its catalogue of arrays for its genomics services. This most recent achievement represents a great step forward for all scientists who work on elucidating the information from the human genome sequencing effort but also for ExonHit's own drug and diagnostic discovery programs. This genome wide SpliceArrayTM is available through ExonHit's service laboratory and our discovery collaboration programs for therapeutic targets and biomarkers" said Dr. Laurent Bracco, Executive Vice President of Technology at ExonHit Therapeutics.

"Our commitment is to advance human healthcare through the identification of high quality targets and biomarkers involved in disease by understanding the diversity caused by alternative splicing. This new SpliceArrayTM, a major component of our discovery engine, will allow us to further accelerate our patent estate to diagnose chronic diseases and will reinforce considerably our capabilities in the field of pharmacogenomics" stated Dr. Bruno Tocque, CEO of ExonHit Therapeutics. "

About ExonHit Therapeutics

www.exonhit.com

ExonHit Therapeutics is the world's leader in the analysis of alternative RNA splicing, a process which when deregulated plays a key role in the onset of various diseases.

ExonHit has a multi-component commercial strategy to capture the maximum value from its leadership in alternative splicing. The Company is already generating revenues from a new generation of microarrays, SpliceArrayTM family of products, that enable life science researchers to detect crucial disease-associated information. These products are marketed worldwide in conjunction with Agilent and Affymetrix. In the field of diagnostics, ExonHit has a major collaboration with bioMerieux to develop completely novel predictive blood-based cancer diagnostics, which could play a key role in improving the treatment of breast cancer and other major cancers and develops its own projects for the detection of other chronic diseases such as Alzheimer'disease or atherosclerosis.

In parallel, ExonHit is developing its own therapeutic pipeline in the field of neurodegenerative diseases and cancer. The Company has advanced drug candidates into clinical trials and is evaluating several promising pre-clinical compounds. ExonHit also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ticker: ALEHT; ISIN: FR0004054427) since November 17, 2005.

Contacts
ExonHit Therapeutics
Bruno Tocque, C.E.O.
Philippe Rousseau, C.F.O.
Tel: +33-1-58-05-47-00
philippe.rousseau@exonhit.com

More from Transportation Industry Products

All Topics

COVID-19 Response Suppliers COVID-19 Response:
Can Your Company Help Provide Critical Supplies?

We are using the power of our platform to aid in the mass shortage of critical supplies. If your company can help provide supplies, capabilities, or materials for products such as N-95 Masks and Tyvek SuitsPlease let us know.

COVID-19 Response Suppliers